Bharat Biotech, founded by Krishna Ella and his wife Suchitra, has been at the forefront of making vaccines for a while. Yet it took a global pandemic for the spotlight to shine on the company.
As India battles the second wave of Covid-19, which has caused havoc across the country, healthcare companies have come to the fore as lifesavers, to ensure the attack of the virus is countered.
For long thought of as a net recipient of global health benefits, India is turning into a global healthcare provider. This will be a major pillar of its diplomacy in the years to come.
For BBIL’s founder Krishna Ella, the roll-out of a made-in-India vaccine, Covaxin, is peppered with challenges. Two recent deals with Brazilian and American firms have now buoyed him.
India is conducting dry runs for the Covid-19 vaccination programme. Fortune India visited one such site, following the trajectory of one health worker, depicting the entire vaccination process.
